Unilever Plc engages in the manufacture and sale of consumer goods. It operates through the following segments: Beauty & Wellbeing, Personal Care, Home Care, Nutrition, and Ice Cream. The Beauty & Wellbeing segment offers hair care, skin care, and prestige beauty and health & wellbeing. The Personal Care segment consists of sales of skin cleansing, deodorant, and oral care products. The Home Care segment comprises of sales of fabric care and a wide range of cleaning products. The Nutrition segment refers to sales of scratch cooking aids, dressings, and tea products. The Ice Cream segment covers primarily ice cream products. The company was founded by Antonius Johannes Jurgens, Samuel van den Bergh, and William Hulme Lever on January 1, 1930 and is headquartered in London, the United Kingdom.
Clinical Trials
42
1 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1930
Active, not recruiting
1
2.4%
Completed
29
69.0%
Recruiting
12
28.6%
No approval data available
- Several high-profile federal health initiatives rely on voluntary industry agreements rather than regulation, and reporting finds the promised changes have largely not arrived on the announced timelines. - The FDA quietly moved its synthetic dye removal deadline from the end of 2026 to the end of 2027, with fewer than 30% of pledged companies meeting their goals. - Health plans reduced prior authorization for medical services by only about 11% as of July, far short of the announced January 2026 target, and promised public dashboards have not launched. - Seventeen drugmakers agreed to lower prices for Medicaid enrollees and cash-paying consumers, but the deals do not cover existing drugs for the more than 200 million Americans with commercial or private coverage.
- Evonik has broken ground on an approximately €80 million biotechnology expansion at its Fermas site in Slovenská Ľupča, Slovakia, targeting completion in early 2028. - The investment adds state-of-the-art downstream fermentation technology to increase capacity for development and manufacture of complex pharmaceutical intermediates. - The expansion will create roughly 50 new jobs and reinforce Fermas as a key Evonik biotechnology hub serving drug substance contract manufacturing. - Fermas, founded in 1992, has evolved from amino acid production into a hub for pharmaceutical, personal care, nutrition and specialty chemical manufacturing.
